1.00
+0.08(+8.70%)
Currency In USD
| Previous Close | 0.92 |
| Open | 0.92 |
| Day High | 1.04 |
| Day Low | 0.91 |
| 52-Week High | 1.8 |
| 52-Week Low | 0.31 |
| Volume | 2.89M |
| Average Volume | 8.49M |
| Market Cap | 29.43M |
| PE | -1.45 |
| EPS | -0.69 |
| Moving Average 50 Days | 0.64 |
| Moving Average 200 Days | 0.94 |
| Change | 0.08 |
If you invested $1000 in Femasys Inc. (FEMY) since IPO date, it would be worth $83.27 as of November 25, 2025 at a share price of $0.999. Whereas If you bought $1000 worth of Femasys Inc. (FEMY) shares 3 years ago, it would be worth $774.57 as of November 25, 2025 at a share price of $0.999.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Femasys Advances Global Growth with Second Partner Order for FemBloc® in Europe
GlobeNewswire Inc.
Nov 10, 2025 2:00 PM GMT
-- Continued rollout of FemBloc, the breakthrough non-surgical permanent contraceptive solution, expands the Company’s presence in key European Markets -- ATLANTA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical
Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million
GlobeNewswire Inc.
Nov 03, 2025 1:30 PM GMT
-- Successful completion of first trial phase enables continued pivotal trial of FemBloc, the only non-surgical permanent birth control, toward U.S. FDA approval -- -- $12 million senior secured convertible notes for total potential proceeds of $58 m
Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe
GlobeNewswire Inc.
Oct 22, 2025 1:00 PM GMT
--Marks key milestone in European commercialization strategy under EU Medical Device Regulation (MDR)-- ATLANTA, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permane